Newly-rebranded MRCT to invest up to £500 million into research

15 June 2017

The UK charity which evolved from the Medical Research Council and has helped to develop Keytruda (pembrolizumab), Entyvio (vedolizumab) and other big-selling therapeutics, is still generously funding medical innovations.

Now called LifeArc, having previously been MRC Technology, the charity has announced plans to invest up to £500 million ($636 million) over the next five years to generate, fund and champion research in antimicrobials, neuroscience, personalized oncology and respiratory medicine.

"The name LifeArc better reflects what we achieve in being the arc or bridge between great science and its application to help patients"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK